Furthermore, our results firstly demonstrate the capacity of CDH17 to regulate the activity of integrin-Ras/Raf/MEK/ERK pathway for cell proliferation in GC, and suggest that CDH17 can serve as an attractive therapeutic target for future research. This evidence concerns the gene MAP2K7 and gastric cancer.